Is There Still a Role for Docetaxel in mHSPC?

Sweeney Christopher, MBBS, Medical Oncologist at the Dana-Farber Cancer Institute and Professor of Medicine at Harvard Medical School, describes treatment selections in metastatic hormone-sensitive prostate cancer (mHSPC).